Medicinal Products

BACTRIM Infant / Child 200 mg / 40 mg

Generic drug of the therapeutic class: Infectiology - Parasitology
active ingredients: Sulfamethoxazole, Trimethoprim
laboratory: Roche

Oral suspension
Bottle (+ spoon-measure of 5 ml) of 100 ml
All forms


They result from the antibacterial and antiparasitic activity of the product, the pharmacokinetic characteristics of sulfamethoxazole and trimethoprim, the risk of adverse effects (especially haematological and cutaneous) and must take into account, in a given country, the evolution of the sensitivity of the germs to the product and other available antibiotics. Depending on the indications and the organisms involved, the antibiotic with the best benefit / risk ratio should be used as a first-line treatment.
They are limited to infections of the child due to sensitive germs (see pharmacological properties).
Especially :
- Curative treatment of Pneumocystis carinii infections.
- Prevention of Pneumocystis carinii infections in immunocompromised patients.
On the other hand :
Taking into account the benefit / risk ratio compared to other products, the epidemiology and the bacterial resistance observed in these pathologies:
- Treatment :
. urinary tract infections,
- otitis and sinusitis, but only after bacteriological documentation,
- certain bronchopulmonary infections,
- digestive infections, and typhoid fever.
Official recommendations concerning the appropriate use of antibacterials should be taken into account.

Dosage BACTRIM Infant / Child 200 mg / 40 mg Oral suspension Bottle (+ measuring spoon of 5 ml) of 100 ml

A 5 ml measuring spoon contains 200 mg of sulfamethoxazole and 40 mg of trimethoprim.
The normal dosage is as follows: 30 mg / kg / day of sulfamethoxazole and 6 mg / kg / day of trimethoprim taken twice daily. In case of severe infections, the dosage can be increased by half.
Special cases :
- Curative treatment of Pneumocystis carinii infections : 100 mg / kg / day of sulfamethoxazole and 20 mg / kg / day of trimethoprim in 2 doses per day.
- Prevention of Pneumocystis carinii infections in HIV-positive children from an age-dependent CD4 cell count or a lymphocyte count of less than 15% of total lymphocytes:
. less than 1 year: CD4 <750 cells / mm3,
. 1 year to 5 years: CD4 <500 cells / mm3,
. more than 6 years: CD4 <200 cells / mm3,
20 to 30 mg / kg / day of sulfamethoxazole and 4 to 6 mg / kg / day of trimethoprim 3 times a week to 1 time per day.
Renal insufficiency:
. creatinine clearance> 30 ml / min: normal dosage,
. 15 ml / min <creatinine clearance <30 ml / min: half dose (same unit dosage, but once daily),
. creatinine clearance <15 ml / min: use only in case of hemodialysis. The dosage is then reduced by half, administered after dialysis; regular verification of plasma concentrations is recommended.
Administration mode :
The administration will be preferably during meals.

Against indications

This medicine MUST NEVER BE USED:
- in the event of a history of hypersensitivity to any of the components (in particular, hypersensitivity to sulphonamides),
- in premature babies and newborns because of the immaturity of their enzymatic systems,
- in case of G6PD deficiency, including in the breastfed child: risk of triggering haemolysis,
- in case of severe damage to the liver parenchyma,
- during breastfeeding if the newborn is less than one month old: the trimethoprim-sulfamethoxazole combination passes into breast milk. Breastfeeding is contraindicated if the mother or child has a G6PD deficiency, to prevent the occurrence of haemolysis. With sulfonamides with a long half-life, nuclear jaundices have been reported in neonates. As a result, breastfeeding is contraindicated when the newborn is less than one month old,
- in case of association with methotrexate (see interactions).
Due to the presence of sucrose, this drug is contraindicated in case of fructose intolerance, glucose-galactose malabsorption syndrome or sucrase-isomaltase deficiency.
. during breastfeeding: beyond 1 month in the newborn, breastfeeding is not recommended,
. in combination with phenytoin, hyperkalemia [potassium salts, potassium diuretics, ACE inhibitors, angiotensin II inhibitors, nonsteroidal anti-inflammatory drugs, heparins (low molecular weight unfractionated), ciclosporin and tacrolimus, trimethoprim (see interactions).
- The use of trimethoprim-sulfamethoxazole is not recommended in patients with macrocytic anemia.
- Pregnancy: It is preferable, as a precautionary measure, not to use the combination sulfamethoxazole / trimethoprim during the first trimester of pregnancy. Studies in animals have shown a teratogenic effect. Clinical decline and published data on a still limited number of patients show no increase in the overall incidence of malformations or neonatal disorders. Two recent studies, however, mention the possibility of specific neural tube and heart damage in case of exposure during the three months following the last menstrual period. The mechanism of action involved would be that of interference with folates. These results must be confirmed and do not justify on their own to advise an abortion. Nevertheless, if the combination sulfamethoxazole-trimethoprim is used in early pregnancy folic acid supplementation may be proposed during the course of treatment, without evaluation to date its effectiveness in the prevention of abnormalities mentioned. In case of congenital G6PD deficiency, the occurrence of neonatal haemolysis is possible.

Bactrim Infant / Child Adverse Effects

- General disorders:
Hypersensitivity reactions have been reported: hyperthermia, angioedema, anaphylactic shock, and anaphylactoid reactions.
Exceptional cases of interstitial lung disease have been reported.
The reported adverse effects, in order of decreasing frequency, are as follows:
- Skin manifestations:
Itchy rash, hives. These events are usually mild and rapidly reversible upon discontinuation of treatment.
Like other sulfonamide-containing drugs, trimethoprim-sulfamethoxazole has been associated with erythema multiforme skin manifestations, Stevens-Johnson syndrome, toxic epidermal necrosis (Lyell's syndrome) and fixed pigmented erythema.
- Digestive disorders :
Nausea, vomiting, epigastralgia, diarrhea (especially due to the presence of glycerol).
Pseudomembranous colitis.
Cases of pancreatitis have been reported with trimethoprim-sulfamethoxazole; one-third of them in immunocompromised patients (transplant, HIV, AIDS).
- Hepatic disorders:
Hepatitis mainly cholestatic, increased transaminases and bilirubin.
- Hematological manifestations:
Cases of thrombocytopenia, leuconeutropenia, agranulocytosis, medullary aplasia, hemolytic anemia seem to be preferentially related to an immunoallergic mechanism. In subjects over 65 years of age and / or deficient in folate, these hematologic events, particularly cases of megaloblastic anemia and cytopenias, seem rather to be a toxic mechanism of dose and duration. Indeed, the product may interfere with folate metabolism.
- Urinary system disorders:
Cases of impaired renal function, interstitial nephropathy, isolated increases in serum creatinine, and crystalluria have been reported.
- Neurological manifestations:
Neuropathies (including peripheral neuropathy and paresthesia). Rare cases of aseptic meningitis, or pseudomeningeal symptoms, ataxia, convulsions, dizziness, and tremors have been reported.
Exceptional cases of uveitis have been described.
- Musculoskeletal system disorders:
Rare cases of arthralgia and myalgia, and isolated cases of rhabdomyolysis have been reported.
- Metabolic disorders:
Cases of hyperkalemia have been reported with trimethoprim-sulfamethoxazole:
. at the usual doses if there is an underlying disorder of potassium metabolism, kidney failure, or taking hyperkalaemic drugs. Close monitoring of serum potassium is then justified,
. in high doses, as used in the treatment of Pneumocystis carinii pneumonia .
In these cases, the increase in serum potassium was progressive and reversible upon discontinuation of treatment.
Cases of hyponatremia and metabolic acidosis have been reported.
Rare cases of hypoglycemia have been observed in non-diabetic patients. They usually appear after a few days of treatment.
- Manifestations in patients with HIV / AIDS infection:
The frequency of adverse effects, especially cutaneous, hyperthermia, leukopenia, increased transaminases and hyperkalemia at high dose, is more important.
Cases of pancreatitis and rhabdomyolysis have been reported in patients who are also receiving treatment that may result in such effects.

Popular Posts

Category Medicinal Products, Next Article